Evidence map›Paper›PMID 35214141›Full record

ArticlePharmaceutics2022

Physicochemical Characterizations and Pharmacokinetic Evaluation of Pentazocine Solid Lipid Nanoparticles against Inflammatory Pain Model.

Zaheer Ullah Khan, Anam Razzaq, Ahsan Khan, Naeem Ur Rehman, Hira Khan, Taous Khan, Ashraf Ullah Khan, Norah A Althobaiti, Farid Menaa, Haroon Iqbal and 1 more

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Self-emulsifying micelles as a drug nanocarrier system for itraconazole oral bioavailability enhancement;Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 4 countries.

Zaheer Ullah KhanDepartment of Pharmacy, Abbottabad Campus, COMSATS University Islamabad, Abbottabad 22060, Pakistan.
Anam RazzaqDepartment of Pharmaceutics, College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China.
Ahsan KhanDepartment of Pharmacy, Abbottabad Campus, COMSATS University Islamabad, Abbottabad 22060, Pakistan.ORCID 0000-0003-1236-0735
Naeem Ur RehmanDepartment of Pharmacy, Abbottabad Campus, COMSATS University Islamabad, Abbottabad 22060, Pakistan.
Hira KhanDivision of Pharmaceutics and Pharmacology, College of Pharmacy, Ohio State University, Colombus, OH 43210, USA.
Taous KhanDepartment of Pharmacy, Abbottabad Campus, COMSATS University Islamabad, Abbottabad 22060, Pakistan.
Ashraf Ullah KhanDepartment of Pharmacy, Quaid-i-Azam University, Islamabad 45320, Pakistan.
Norah A AlthobaitiDepartment of Biology, College of Science and Humanities-Al Quwaiiyah, Shaqra University, Al Quwaiiyah 19257, Saudi Arabia.
Farid MenaaDepartment of Oncology and Nanomedicine, California Innovations Corporation, San Diego, CA 92037, USA.ORCID 0000-0002-0258-7322
Haroon IqbalInstitute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences (CAS), The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou 310022, China.ORCID 0000-0002-7908-8804
Naveed Ullah KhanDepartment of Pharmacy, Gujrat Campus, University of Lahore, Lahore 50700, Pakistan.
COMSATS University Islamabad · PKQuaid-i-Azam University · PKCalifornia Medical Innovations Institute · USShaqra University · SASoochow University · CNThe Ohio State University · USUniversity of Lahore · PKZhejiang Cancer Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pentazocine (PTZ), a narcotic-antagonist analgesic, has been extensively used in the treatment of initial carcinogenic or postoperative pain. Hepatic first-pass metabolism results in low oral bioavailability and high dose wastage. Herein, 10 mg (-)-Pentazocine (HPLC-grade) was incorporated to solid lipid nanoparticles (SLNs) using a double water-oil-water (

Indexed as

controlled and sustained drug releasefirst-pass metabolisminflammationoral bioavailabilitypentazocinesolid lipid nanoparticles

Identifiers

PMID35214141
PMCPMC8876599
OpenAlexW4213171710

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.